{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:29:48Z","timestamp":1772857788919,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:00:00Z","timestamp":1526947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.vaccine.2018.05.046","type":"journal-article","created":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T23:54:02Z","timestamp":1526687642000},"page":"4102-4111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study"],"prefix":"10.1016","volume":"36","author":[{"given":"Ghassan","family":"Dbaibo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Tinoco Favila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magali","family":"Traskine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archana","family":"Jastorff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Van der Wielen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.05.046_b0005","unstructured":"World Health Organization. Meningococcal meningitis factsheet No 141. Updated November 2015. Available from: <http:\/\/www.who.int\/mediacentre\/factsheets\/fs141\/en\/> [accessed 2017 January 19]."},{"key":"10.1016\/j.vaccine.2018.05.046_b0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"10.1016\/j.vaccine.2018.05.046_b0015","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jadohealth.2016.04.012","article-title":"The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines","volume":"59","author":"Pelton","year":"2016","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2018.05.046_b0020","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","article-title":"The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004\u20132014","volume":"35","author":"Whittaker","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.046_b0025","unstructured":"Preparedness for outbreaks of meningococcal meningitis due to Neisseria meningitidis serogroup C in Africa: recommendations from a WHO expert consultation. Wkly Epidemiol Rec. 2015;90:633\u20136."},{"key":"10.1016\/j.vaccine.2018.05.046_b0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/20477724.2016.1274068","article-title":"Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa","volume":"111","author":"Mohammed","year":"2017","journal-title":"Pathog Glob Health"},{"key":"10.1016\/j.vaccine.2018.05.046_b0035","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.vaccine.2013.04.036","article-title":"Emergence of serogroup X meningococcal disease in Africa: need for a vaccine","volume":"31","author":"Xie","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.046_b0040","first-page":"E116","article-title":"Epidemiology of Neisseria meningitidis infections: case distribution by age and relevance of carriage","volume":"56","author":"Gabutti","year":"2015","journal-title":"J Prev Med Hyg"},{"key":"10.1016\/j.vaccine.2018.05.046_b0045","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1517\/14712590802538455","article-title":"Meningococcal tetravalent conjugate vaccine","volume":"8","author":"Smith","year":"2008","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2018.05.046_b0050","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.cmi.2016.01.007","article-title":"ESCMID guideline: diagnosis and treatment of acute bacterial meningitis","volume":"22","author":"van de Beek","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2018.05.046_b0055","unstructured":"WHO. Meningococcal vaccines: WHO position paper. Wkly Epidemiol Rec. 2011;47:521\u201339."},{"key":"10.1016\/j.vaccine.2018.05.046_b0060","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s40121-016-0107-0","article-title":"Meningococcal vaccinations","volume":"5","author":"Crum-Cianflone","year":"2016","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2018.05.046_b0065","unstructured":"European Medicines Agency. Nimenrix. Summary of product characteristics. Available from: <http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002226\/WC500127663.pdf> [accessed 2017 February 7]."},{"key":"10.1016\/j.vaccine.2018.05.046_b0070","first-page":"1825","article-title":"Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix): a review of its immunogenicity, safety, co-administration, and antibody persistence","volume":"12","author":"Assaf-Casals","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.05.046_b0075","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2165\/11209580-000000000-00000","article-title":"Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix)","volume":"72","author":"Croxtall","year":"2012","journal-title":"Drugs"},{"key":"10.1016\/j.vaccine.2018.05.046_b0080","unstructured":"World Health Organization. WHO prequalified vaccines. Meningococcal ACYW-135 (conjugate vaccine) Nimenrix. Available from: <https:\/\/extranet.who.int\/gavi\/PQ_Web\/PreviewVaccine.aspx?nav=0&ID=301> [accessed 2017 September 25]."},{"key":"10.1016\/j.vaccine.2018.05.046_b0085","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1097\/INF.0000000000001484","article-title":"Safety and immunogenicity of the quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine coadministered with routine childhood vaccines in European infants: an open, randomized trial","volume":"36","author":"Merino Arribas","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.05.046_b0090","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1128\/CDLI.10.5.780-786.2003","article-title":"Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England","volume":"10","author":"Andrews","year":"2003","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.vaccine.2018.05.046_b0095","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.05.046_b0100","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.05.046_b0105","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1016\/j.vaccine.2015.07.019","article-title":"Serum bactericidal antibody assays - the role of complement in infection and immunity","volume":"33","author":"McIntosh","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.046_b0110","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","article-title":"An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix hexa is immunogenic, with an acceptable safety profile in 12\u201323-month-old children","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.046_b0115","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/INF.0b013e3182784143","volume":"32","author":"Ruiz-Palacios","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.05.046_b0120","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.046_b0125","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.vaccine.2016.05.009","article-title":"Safety and immunogenicity of a CRM or TT conjugated meningococcal vaccine in healthy toddlers","volume":"34","author":"Bona","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.046_b0130","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/hv.22166","article-title":"Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunothe."},{"key":"10.1016\/j.vaccine.2018.05.046_b0135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/INF.0b013e31823dce5c","article-title":"Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants","volume":"31","author":"Klein","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.05.046_b0140","doi-asserted-by":"crossref","first-page":"e100651","DOI":"10.1371\/journal.pone.0100651","article-title":"Timing of an adolescent booster after single primary meningococcal serogroup C conjugate immunization at young age; an intervention study among Dutch teenagers","volume":"9","author":"Stoof","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.05.046_b0145","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1097\/INF.0b013e318199f62d","article-title":"Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines","volume":"28","author":"Chevallier","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.05.046_b0150","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.vaccine.2004.08.030","article-title":"Booster vaccination with hexavalent DTPa-HBV-IPV\/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV\/Hib + HBV administered separately","volume":"23","author":"Saenger","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.046_b0155","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/S0140-6736(07)61016-2","article-title":"Epidemic meningitis, meningococcaemia, and Neisseria meningitidis","volume":"369","author":"Stephens","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.05.046_b0160","doi-asserted-by":"crossref","first-page":"e574","DOI":"10.1016\/j.ijid.2012.03.011","article-title":"Meningococcal disease in the Middle East and North Africa: an important public health consideration that requires further attention","volume":"16","author":"Ceyhan","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.046_b0165","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.vaccine.2006.11.018","article-title":"The epidemiology of pneumococcal, meningococcal, and Haemophilus disease in the Middle East and North Africa (MENA) region-current status and needs","volume":"25","author":"Hausdorff","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.046_b0170","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/INF.0000000000000228","article-title":"A consensus statement: meningococcal disease among infants, children and adolescents in Latin America","volume":"33","author":"Ruttimann","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2018.05.046_b0175","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1016\/j.vaccine.2015.10.055","article-title":"The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations","volume":"33","author":"Safadi","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.05.046_b0180","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1586\/14760584.2013.814879","article-title":"The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative","volume":"12","author":"Safadi","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.05.046_b0185","unstructured":"WHO vaccine-preventable diseases: monitoring system. 2017 global summary. Available at: <http:\/\/apps.who.int\/immunization_monitoring\/globalsummary\/schedules> [accessed 12 June 2017]."},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2018.05.046_b0190","doi-asserted-by":"crossref","first-page":"S594","DOI":"10.1093\/cid\/civ508","article-title":"Modeling long-term vaccination strategies with MenAfriVac in the African Meningitis Belt","volume":"61","author":"Karachaliou","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2018.05.046_b0195","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0b013e31828693c5","article-title":"One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children","volume":"32","author":"Klein","year":"2013","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18306662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18306662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T05:00:30Z","timestamp":1604293230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18306662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":39,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["S0264410X18306662"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.046","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: A phase III, randomized study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 GlaxoSmithKline Biologicals. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}